Personalized risk for clinical progression in cognitively normal subjects—the ABIDE project

Personalized risk for clinical progression in cognitively normal subjects—the ABIDE project

Abstract Background Biomarkers such as cerebrospinal fluid (CSF) and magnetic resonance imaging (MRI) have predictive value for progression to dementia in patients with mild cognitive impairment (MCI). The pre-dementia stage takes far longer, and the interpretation of biomarker findings is particula...

Full description

Bibliographic Details
Main Authors: Ingrid S. van Maurik, Rosalinde E. R. Slot, Sander C. J. Verfaillie, Marissa D. Zwan, Femke H. Bouwman, Niels D. Prins, Charlotte E. Teunissen, Philip Scheltens, Frederik Barkhof, Mike P. Wattjes, Jose Luis Molinuevo, Lorena Rami, Steffen Wolfsgruber, Oliver Peters, Frank Jessen, Johannes Berkhof, Wiesje M. van der Flier, for the Alzheimer’s Disease Neuroimaging Initiative
Format: Article
Language:English
Published: BMC 2019-04-01
Series:Alzheimer’s Research & Therapy
Subjects:
Biomarkers
Progression
Cerebrospinal fluid
Magnetic resonance imaging
Online Access:http://link.springer.com/article/10.1186/s13195-019-0487-y

Internet

http://link.springer.com/article/10.1186/s13195-019-0487-y

Similar Items